IHS Chemical Week

Chemical Week Magazine :: Pharmaceuticals & Fine Chemicals

Merck Adds to Biotech Center

2:55 AM MST | November 24, 2008 | Deepti Ramesh

Merck Serono, a unit of Merck KGaA, says it will invest about €300 million ($390 million) to expand production of cetuximab at its Merck Serono Biotech Center (MSBC) at Corsier-sur-Vevey, Switzerland. The expansion is expected to be completed in 2012, pending inspection by worldwide health authorities. Cetuximab is a monoclonal antibody used in the treatment of colorectal, head, and neck cancers. The expansion includes adding two dedicated production suites with 120,000 liters of bioreactor capacity, a wastewater treatment station, and a logistic center to...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.

Risk Free Trial

Email Address

First Name

Last Name

Click here to register and get your RISK-FREE access to chemweek.com

Not an IHS Chemical Week
24/7 member yet?

Here's why you should be:

  • Searchable online archive access of the last 2 years of Chemical Week.
  • Print or digital magazine subscription
  • Price and market change alerts
  • Economic data and statistics
  • Buyers' Guides
  • Webcasts | whitepapers

 

 

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2014 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa